Also, our reported results showing that an inhibitor of PARP1 (ABT-888) sensitizes colon cancer cell lines to irinotecan (Davidson et al., 2013) have lead to an ongoing clinical trial (clicaltrials.gov, Abbvie, NCT02305758). The gene discussed is PARP1; the disease is colonic neoplasm.